[225Ac]-anti-EGFRvIII

N/A

Report date: 2025/10/31 15:08:07

Base Information

Drug Name[225Ac]-anti-EGFRvIII

Drug Alias NameN/A

ClassificationRadiation-emitting products > Nuclides > Actinium > 225AcRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionAnti-EGFRvIII

TargetsEpidermal growth factor receptor variant III

Therapy Area/IndicationsGlioblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanada

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesFusion Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesFusion Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsGlioblastoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A